Aficamten-MYQORZO is a medicine that treats what

Aficamten (generic name aficamten, trade name MYQORZO) is a new cardiac myosin inhibitor, specially developed for patients with symptomatic obstructive hypertrophic cardiomyopathy. Its core function is to improve cardiac function and alleviate disease-related clinical symptoms, and provides a targeted treatment plan for this disease.

Hypertrophic cardiomyopathy (HCM) is typically characterized by abnormal thickening of the myocardium. The lesions can cause the left ventricular cavity to shrink and increase the stiffness of the ventricular wall, impairing its diastolic and blood filling functions. Patients often experience chest pain, dizziness, and shortness of breath after activity. In severe cases, they may faint during physical activities due to limited heart function, which significantly affects the quality of life and ability to move.

Afkate's therapeutic mechanism is highly targeted. By blocking the core molecule that drives myocardial contraction - cardiac myosin, it reduces the number of active actin-myosin cross-bridges in the cardiac cycle, fundamentally inhibits myocardial overcontraction in patients with hypertrophic cardiomyopathy, and accurately improves the systolic and diastolic functions of the heart.

The drug's FDA approval was based on the positive results of the Phase 3 clinical trial SEQUOIA-HCM, which showed that compared with the placebo group, the exercise capacity of patients treated with Afkat for 24 weeks was significantly improved: as measured by cardiopulmonary exercise testing, the patient's maximum oxygen uptake increased by 1.8 ml/kg/min from baseline, while there was no improvement in the placebo group, and the least squares mean difference between the groups was 1.74 ml/min. kg/min, the difference in efficacy was statistically significant.

Afkatai is an oral tablet that can be taken once a day and is convenient to take. It should be noted that this drug carries a box warning about the risk of heart failure, which may reduce the patient's left ventricular ejection fraction and cause systolic dysfunction heart failure; its common adverse reaction is hypertension, with an incidence rate of about 8%, and relevant indicators need to be monitored during medication.

Reference materials:https://www.drugs.com/history/myqorzo.html